BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/19/2015 5:28:00 PM | Browse: 732 | Download: 584
Publication Name World Journal of Hepatology
Manuscript ID 16100
Country of Manuscript Source Greece
Received
2014-12-26 08:48
Peer-Review Started
2014-12-30 09:31
To Make the First Decision
2015-01-20 13:41
Return for Revision
2015-01-23 09:28
Revised
2015-02-10 00:00
Second Decision
2015-02-27 09:40
Accepted by Journal Editor-in-Chief
2015-02-27 16:09
Accepted by Company Editor-in-Chief
2015-03-18 17:19
Articles in Press
2015-03-18 17:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-05-01 18:06
Publish the Manuscript Online
2015-05-19 17:28
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript type Review
Article Title Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues
Manuscript Source Invited Manuscript
All Author List Irene Rapti and Stephanos Hadziyannis
Funding Agency and Grant Number
Correspondence To Stephanos Hadziyannis, Emeritus Professor of Medicine and Hepatology, Liver Unit and its Molecular Biology Laboratory, National and Kapodistrian University of Athens, Evgenidion Hospital of Athens, 4 Dirrachiou Str., 15669 Athens, Greece. hadziyannis@ath.forthnet.gr
Keywords Chronic hepatitis B; Cirrhosis; Hepatocellular carcinoma; Hepatitis B virus; Treatment; Interferon; Lamivudine; Adefovir; Entecavir; Tenofovir; Virological remission; Nucleos(t)ide analogues
Core Tip Hepatocellular carcinoma (HCC) represents a major health problem worldwide. It develops on the grounds of chronic liver disease, with chronic hepatitis B virus infection (CHB) being responsible for more than 50% of HCC worldwide. Currently, the vast majority of patients with CHB are being treated with nucleos(t)ide analogues, which have changed the natural history of the disease, reducing at a considerable extent its long-term consequences. However, although the risk of HCC has also been reduced, it has not been eliminated even after HBsAg loss or seroconversion. Therefore, constant surveillance, according to guidelines should never be omitted, unless new more potent treatment options are identified.
Publish Date 2015-05-19 17:28
Citation Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol 2015; 7(8): 1064-1073
Url http://www.wjgnet.com/1948-5182/full/v7/i8/1064.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i8.1064
Full Article (PDF) WJH-7-1064.pdf
Full Article (Word) WJH-7-1064.doc
Manuscript File 16100-Review.docx
Answering Reviewers 16100-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form 16100-Conflict-of-interest statement.pdf
Copyright License Agreement 16100-Copyright assignment.pdf
Peer-review Report 16100-Peer-review(s).pdf
Scientific Misconduct Check 16100-Scientific misconduct check.pdf
Scientific Editor Work List 16100-Scientific editor work list.pdf